Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Short Interest Report: AMC Entertainment shorts sound retreat » 15:25
05/14/21
05/14
15:25
05/14/21
15:25
FIZZ

National Beverage

$46.15 /

+1.06 (+2.35%)

, SFIX

Stitch Fix

$43.01 /

+1.9 (+4.62%)

, BBBY

Bed Bath & Beyond

$24.97 /

+1.65 (+7.08%)

, RCKT

Rocket Pharmaceuticals

$40.49 /

-0.535 (-1.30%)

, AMC

AMC Entertainment

$12.72 /

-0.04 (-0.31%)

, CRTO

Criteo

$36.49 /

+0.37 (+1.02%)

, IWF

iShares Russell 1000 Growth

$251.66 /

+4.9 (+1.99%)

, IWD

iShares Russell 1000 Value

$160.93 /

+2.26 (+1.42%)

Welcome to this week’s…

ShowHide Related Items >><<
SFIX Stitch Fix
$43.01 /

+1.9 (+4.62%)

RCKT Rocket Pharmaceuticals
$40.49 /

-0.535 (-1.30%)

FIZZ National Beverage
$46.15 /

+1.06 (+2.35%)

CRTO Criteo
$36.49 /

+0.37 (+1.02%)

BBBY Bed Bath & Beyond
$24.97 /

+1.65 (+7.08%)

AMC AMC Entertainment
$12.72 /

-0.04 (-0.31%)

FIZZ National Beverage
$46.15 /

+1.06 (+2.35%)

02/03/21 UBS
National Beverage downgraded to Sell from Neutral at UBS
10/20/20
Fly Intel: Top five analyst upgrades
10/20/20 Jefferies
National Beverage upgraded to Hold on better La Croix market share at Jefferies
10/20/20 Jefferies
National Beverage upgraded to Hold from Underperform at Jefferies
SFIX Stitch Fix
$43.01 /

+1.9 (+4.62%)

04/05/21 Evercore ISI
Stitch Fix initiated with an Outperform at Evercore ISI
03/09/21
Fly Intel: Top five analyst downgrades
03/09/21 Canaccord
Stitch Fix price target lowered to $68 from $72 at Canaccord
03/09/21 KeyBanc
Stitch Fix price target lowered to $75 from $95 at KeyBanc
BBBY Bed Bath & Beyond
$24.97 /

+1.65 (+7.08%)

04/19/21 JPMorgan
Bed Bath & Beyond price target raised to $29 from $23 at JPMorgan
04/16/21 Loop Capital
Bed Bath & Beyond price target lowered to $24 from $30 at Loop Capital
04/15/21 Wedbush
Bed Bath & Beyond price target lowered to $27 from $33 at Wedbush
04/14/21 Wells Fargo
Bed Bath & Beyond continues to cede market share, says Wells Fargo
RCKT Rocket Pharmaceuticals
$40.49 /

-0.535 (-1.30%)

04/01/21 SVB Leerink
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink
03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
AMC AMC Entertainment
$12.72 /

-0.04 (-0.31%)

05/14/21 B. Riley
AMC Entertainment price target raised to $16 from $13 at B. Riley
04/16/21 B. Riley
AMC CEO update on share issuance a positive, says B. Riley
04/05/21 B. Riley
B. Riley upgrades AMC to Buy with $13 target after 'impressive' weekend
04/05/21 B. Riley
AMC Entertainment upgraded to Buy from Neutral at B. Riley Securities
CRTO Criteo
$36.49 /

+0.37 (+1.02%)

05/04/21 Truist
Criteo price target raised to $45 from $37 at Truist
05/03/21 Truist
Criteo price target raised to $45 from $37 at Truist
03/26/21 JMP Securities
Criteo upgraded to Outperform from Market Perform at JMP Securities
03/26/21 JMP Securities
Criteo upgraded to Outperform from Market Perform at JMP Securities
IWF iShares Russell 1000 Growth
$251.66 /

+4.9 (+1.99%)

IWD iShares Russell 1000 Value
$160.93 /

+2.26 (+1.42%)

SFIX Stitch Fix
$43.01 /

+1.9 (+4.62%)

RCKT Rocket Pharmaceuticals
$40.49 /

-0.535 (-1.30%)

FIZZ National Beverage
$46.15 /

+1.06 (+2.35%)

CRTO Criteo
$36.49 /

+0.37 (+1.02%)

BBBY Bed Bath & Beyond
$24.97 /

+1.65 (+7.08%)

AMC AMC Entertainment
$12.72 /

-0.04 (-0.31%)

  • 10
    Dec
SFIX Stitch Fix
$43.01 /

+1.9 (+4.62%)

CRTO Criteo
$36.49 /

+0.37 (+1.02%)

BBBY Bed Bath & Beyond
$24.97 /

+1.65 (+7.08%)

AMC AMC Entertainment
$12.72 /

-0.04 (-0.31%)

SFIX Stitch Fix
$43.01 /

+1.9 (+4.62%)

RCKT Rocket Pharmaceuticals
$40.49 /

-0.535 (-1.30%)

IWF iShares Russell 1000 Growth
$251.66 /

+4.9 (+1.99%)

FIZZ National Beverage
$46.15 /

+1.06 (+2.35%)

AMC AMC Entertainment
$12.72 /

-0.04 (-0.31%)

SFIX Stitch Fix
$43.01 /

+1.9 (+4.62%)

FIZZ National Beverage
$46.15 /

+1.06 (+2.35%)

CRTO Criteo
$36.49 /

+0.37 (+1.02%)

BBBY Bed Bath & Beyond
$24.97 /

+1.65 (+7.08%)

AMC AMC Entertainment
$12.72 /

-0.04 (-0.31%)

Hot Stocks
Rocket Pharmaceuticals presents gene therapy program data at ASGCT » 07:13
05/13/21
05/13
07:13
05/13/21
07:13
RCKT

Rocket Pharmaceuticals

$41.61 /

-0.42 (-1.00%)

Rocket Pharmaceuticals…

Rocket Pharmaceuticals announced clinical data from its Fanconi Anemia, or FA, Leukocyte Adhesion Deficiency-I, or LAD-I, and Pyruvate Kinase Deficiency, or PKD, gene therapy programs presented at the American Society of Gene and Cell Therapy, or ASGCT. The data described in the presentation are from nine pediatric patients treated with RP-L102, Rocket's ex vivo lentiviral gene therapy candidate for FA. RP-L102 demonstrated a highly favorable safety profile with all subjects being treated without conditioning and with no sign of dysplasia or other concerning features. One patient experienced a Grade 2 transient infusion-related reaction. Increasing evidence of engraftment was observed in two patients with at least 15-months of follow-up and four patients with at least 6-months of follow-up as indicated by peripheral blood VCN. Patient 2, who was further along in bone marrow failure and also had complications due to a previously disclosed influenza B infection contracted during the early stage of treatment, was withdrawn from the trial at 18-months post-treatment. At 24-months post-treatment, Patient 1 demonstrated a 16% BM progenitor resistance to 10 nM MMC and peripheral blood VCN levels of 0.32. At 15-months post-treatment, Patient 3 demonstrated a 29% BM progenitor resistance to 10 nM MMC and peripheral blood VCN levels of 0.12. At six-months post-treatment, Patients 4 and 5 had early evidence of BM progenitor resistance with 25% and 14% respectively to 10 nM MMC, consistent with the BM VCNs observed at this timepoint. Patient 4 and 5 also demonstrated peripheral blood VCN levels of 0.07 and 0.06, respectively. Patient 6 demonstrated peripheral blood VCN levels of 0.08 at 4-months post-treatment and Patient 7 demonstrated peripheral blood VCN levels of 0.04 at 6-months post-treatment. BM assessments in Patients 6 and 7 were deferred due to COVID-19 travel concerns. Patients 8 and 9 were treated more recently with less than 6-months follow-up, and one demonstrated detectable VCN.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$41.61 /

-0.42 (-1.00%)

RCKT Rocket Pharmaceuticals
$41.61 /

-0.42 (-1.00%)

04/01/21 SVB Leerink
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink
03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
RCKT Rocket Pharmaceuticals
$41.61 /

-0.42 (-1.00%)

  • 10
    Dec
RCKT Rocket Pharmaceuticals
$41.61 /

-0.42 (-1.00%)

Earnings
Rocket Pharmaceuticals reports Q1 EPS (65c), consensus (69c) » 16:01
05/10/21
05/10
16:01
05/10/21
16:01
RCKT

Rocket Pharmaceuticals

$43.90 /

+0.15 (+0.34%)

"I am pleased that…

"I am pleased that we began 2021 with sustained momentum across clinical, regulatory and manufacturing activities as reflected in our exciting PKD and LAD-I results, advancement of the pipeline toward regulatory submissions, and continued progress of our GMP manufacturing facility," said Gaurav Shah, M.D., Chief Executive Officer of Rocket. "New data readouts and designations from regulatory agencies continue to validate and reinforce the transformative potential of our gene therapies for patients suffering from rare diseases with no current drug treatments. We continued to strengthen our world class operations and capabilities as we added to our leadership team and fortified our balance sheet."

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$43.90 /

+0.15 (+0.34%)

RCKT Rocket Pharmaceuticals
$43.90 /

+0.15 (+0.34%)

04/01/21 SVB Leerink
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink
03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
RCKT Rocket Pharmaceuticals
$43.90 /

+0.15 (+0.34%)

  • 10
    Dec
RCKT Rocket Pharmaceuticals
$43.90 /

+0.15 (+0.34%)

Over a quarter ago
Conference/Events
Chardan to hold a virtual summit » 04:55
04/27/21
04/27
04:55
04/27/21
04:55
OXBDF

Oxford Biomedica

$15.25 /

-0.165 (-1.07%)

, AVRO

Avrobio

$11.80 /

+0.475 (+4.19%)

, CTLT

Catalent

$115.74 /

+0.91 (+0.79%)

, FIXX

Homology Medicines

$6.88 /

+0.1 (+1.47%)

, FRLN

Freeline

$12.61 /

+0.08 (+0.64%)

, LZAGY

Lonza

$60.74 /

-0.365 (-0.60%)

, MBIO

Mustang Bio

$3.29 /

+0.13 (+4.12%)

, MGTX

MeiraGTx

$14.51 /

+1 (+7.40%)

, ORTX

Orchard Therapeutics

$6.26 /

+0.1 (+1.62%)

, PASG

Passage Bio

$17.99 /

+1.07 (+6.32%)

, QURE

uniQure

$34.97 /

+2.72 (+8.43%)

, RCKT

Rocket Pharmaceuticals

$46.35 /

+1.55 (+3.46%)

, RGNX

Regenxbio

$35.48 /

+1.13 (+3.29%)

, SLDB

Solid Biosciences

$5.19 /

+0.095 (+1.86%)

, TSHA

Taysha Gene Therapies

$24.35 /

+1.6 (+7.03%)

5th Annual Genetic…

5th Annual Genetic Medicines Manufacturing Virtual Summit to be held on April 26-27.

ShowHide Related Items >><<
TSHA Taysha Gene Therapies
$24.35 /

+1.6 (+7.03%)

SLDB Solid Biosciences
$5.19 /

+0.095 (+1.86%)

RGNX Regenxbio
$35.48 /

+1.13 (+3.29%)

RCKT Rocket Pharmaceuticals
$46.35 /

+1.55 (+3.46%)

QURE uniQure
$34.97 /

+2.72 (+8.43%)

PASG Passage Bio
$17.99 /

+1.07 (+6.32%)

OXBDF Oxford Biomedica
$15.25 /

-0.165 (-1.07%)

ORTX Orchard Therapeutics
$6.26 /

+0.1 (+1.62%)

MGTX MeiraGTx
$14.51 /

+1 (+7.40%)

MBIO Mustang Bio
$3.29 /

+0.13 (+4.12%)

LZAGY Lonza
$60.74 /

-0.365 (-0.60%)

FRLN Freeline
$12.61 /

+0.08 (+0.64%)

FIXX Homology Medicines
$6.88 /

+0.1 (+1.47%)

CTLT Catalent
$115.74 /

+0.91 (+0.79%)

AVRO Avrobio
$11.80 /

+0.475 (+4.19%)

OXBDF Oxford Biomedica
$15.25 /

-0.165 (-1.07%)

10/09/20 RBC Capital
Oxford Biomedica still a strong investment proposition, says RBC Capital
07/27/20 RBC Capital
Oxford Biomedica initiated with an Outperform at RBC Capital
07/27/20 RBC Capital
Oxford Biomedica initiated with an Outperform at RBC Capital
AVRO Avrobio
$11.80 /

+0.475 (+4.19%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
02/17/21 Mizuho
Avrobio selloff on Bluebird news a buying opportunity, says Mizuho
CTLT Catalent
$115.74 /

+0.91 (+0.79%)

04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/02/21 Argus
Catalent price target raised to $140 from $130 at Argus
02/03/21 UBS
Catalent price target raised to $135 from $115 at UBS
02/03/21 RBC Capital
Catalent price target raised to $137 from $125 at RBC Capital
FIXX Homology Medicines
$6.88 /

+0.1 (+1.47%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
FRLN Freeline
$12.61 /

+0.08 (+0.64%)

03/22/21 Mizuho
Freeline initiated with a Buy at Mizuho
03/01/21 Stifel
Freeline initiated with a Buy at Stifel
11/25/20 Redburn
Freeline initiated with a Neutral at Redburn
09/01/20 Evercore ISI
Freeline initiated with an Outperform at Evercore ISI
LZAGY Lonza
$60.74 /

-0.365 (-0.60%)

02/23/21 JPMorgan
Lonza upgraded to Overweight from Neutral at JPMorgan
02/16/21 Deutsche Bank
Lonza price target raised to CHF 680 from CHF 630 at Deutsche Bank
02/10/21 Berenberg
Lonza price target raised to CHF 690 from CHF 410 at Berenberg
02/02/21 Morgan Stanley
Lonza price target raised to CHF 645 from CHF 630 at Morgan Stanley
MBIO Mustang Bio
$3.29 /

+0.13 (+4.12%)

12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
10/27/20 B. Riley
Mustang Bio selloff not related to fundamentals, says B. Riley Securities
10/26/20 Oppenheimer
Oppenheimer sees case study supporting MB-105 development in prostate cancer
10/26/20 H.C. Wainwright
Mustang Bio's Phase 1 data in PSCA-mCRPC 'encouraging,' says H.C. Wainwright
MGTX MeiraGTx
$14.51 /

+1 (+7.40%)

02/16/21 Chardan
MeiraGTx called a Top Pick for 2021 at Chardan
12/17/20 Chardan
Chardan boosts MeiraGTx target to $55, say buy shares 'now'
12/17/20 Piper Sandler
Piper says MeiraGTx not getting credit for RIX gene therapy that 'clearly works'
10/22/20 RBC Capital
MeiraGTx initiated with an Outperform at RBC Capital
ORTX Orchard Therapeutics
$6.26 /

+0.1 (+1.62%)

03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
PASG Passage Bio
$17.99 /

+1.07 (+6.32%)

04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/08/21 Chardan
Passage Bio price target raised to $45 from $35 at Chardan
03/04/21 Citi
Citi remains buyer of Passage Bio into first clinical data
03/04/21 Goldman Sachs
Passage Bio upgraded to Buy from Neutral at Goldman Sachs
QURE uniQure
$34.97 /

+2.72 (+8.43%)

04/26/21 Chardan
Chardan sees 'stock momentum' for uniQure after clinical hold lift
04/26/21 Credit Suisse
uniQure assumed with an Outperform at Credit Suisse
04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Mizuho
uniQure upgraded to Buy on favorable risk/reward at Mizuho
RCKT Rocket Pharmaceuticals
$46.35 /

+1.55 (+3.46%)

04/01/21 SVB Leerink
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink
03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
RGNX Regenxbio
$35.48 /

+1.13 (+3.29%)

02/09/21 Morgan Stanley
Sarepta denied motion to dismiss 'Wilson Wolf' case, says Morgan Stanley
01/20/21 RBC Capital
Regenxbio price target raised to $50 from $42 at RBC Capital
01/06/21 Chardan
Regenxbio named top 2021 pick with $100 target at Chardan
SLDB Solid Biosciences
$5.19 /

+0.095 (+1.86%)

03/16/21 Chardan
Solid Biosciences price target raised to $20 from $12.50 at Chardan
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform at SVB Leerink
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink
TSHA Taysha Gene Therapies
$24.35 /

+1.6 (+7.03%)

04/12/21 Chardan
Taysha Gene Therapies price target raised to $67.50 from $60 at Chardan
03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
TSHA Taysha Gene Therapies
$24.35 /

+1.6 (+7.03%)

SLDB Solid Biosciences
$5.19 /

+0.095 (+1.86%)

RGNX Regenxbio
$35.48 /

+1.13 (+3.29%)

RCKT Rocket Pharmaceuticals
$46.35 /

+1.55 (+3.46%)

QURE uniQure
$34.97 /

+2.72 (+8.43%)

PASG Passage Bio
$17.99 /

+1.07 (+6.32%)

ORTX Orchard Therapeutics
$6.26 /

+0.1 (+1.62%)

MGTX MeiraGTx
$14.51 /

+1 (+7.40%)

MBIO Mustang Bio
$3.29 /

+0.13 (+4.12%)

FIXX Homology Medicines
$6.88 /

+0.1 (+1.47%)

CTLT Catalent
$115.74 /

+0.91 (+0.79%)

AVRO Avrobio
$11.80 /

+0.475 (+4.19%)

  • 07
    Apr
  • 19
    Mar
  • 22
    Jan
  • 08
    Jan
  • 10
    Dec
  • 23
    Nov
  • 20
    Nov
  • 19
    Nov
  • 24
    Sep
  • 07
    Aug
  • 11
    Jun
  • 11
    Jun
CTLT Catalent
$115.74 /

+0.91 (+0.79%)

SLDB Solid Biosciences
$5.19 /

+0.095 (+1.86%)

RGNX Regenxbio
$35.48 /

+1.13 (+3.29%)

RCKT Rocket Pharmaceuticals
$46.35 /

+1.55 (+3.46%)

QURE uniQure
$34.97 /

+2.72 (+8.43%)

PASG Passage Bio
$17.99 /

+1.07 (+6.32%)

FIXX Homology Medicines
$6.88 /

+0.1 (+1.47%)

CTLT Catalent
$115.74 /

+0.91 (+0.79%)

AVRO Avrobio
$11.80 /

+0.475 (+4.19%)

PASG Passage Bio
$17.99 /

+1.07 (+6.32%)

Conference/Events
Chardan to hold a virtual summit » 09:30
04/26/21
04/26
09:30
04/26/21
09:30
OXBDF

Oxford Biomedica

$15.42 /

+0.21 (+1.38%)

, AVRO

Avrobio

$11.37 /

+0.03 (+0.26%)

, CTLT

Catalent

$114.83 /

+1.52 (+1.34%)

, FIXX

Homology Medicines

$6.78 /

+0.04 (+0.59%)

, FRLN

Freeline

$12.53 /

-0.11 (-0.87%)

, LZAGY

Lonza

$61.10 /

+0.03 (+0.05%)

, MBIO

Mustang Bio

$3.16 /

-0.03 (-0.94%)

, MGTX

MeiraGTx

$13.59 /

-0.51 (-3.62%)

, ORTX

Orchard Therapeutics

$6.17 /

+0.18 (+3.01%)

, PASG

Passage Bio

$16.92 /

-0.82 (-4.62%)

, QURE

uniQure

$32.25 /

-0.66 (-2.01%)

, RCKT

Rocket Pharmaceuticals

$44.80 /

+0.35 (+0.79%)

, RGNX

Regenxbio

$34.25 /

-0.48 (-1.38%)

, SLDB

Solid Biosciences

$5.09 /

+0.195 (+3.98%)

, TSHA

Taysha Gene Therapies

$22.77 /

-0.35 (-1.51%)

5th Annual Genetic…

5th Annual Genetic Medicines Manufacturing Virtual Summit to be held on April 26-27.

ShowHide Related Items >><<
TSHA Taysha Gene Therapies
$22.77 /

-0.35 (-1.51%)

SLDB Solid Biosciences
$5.09 /

+0.195 (+3.98%)

RGNX Regenxbio
$34.25 /

-0.48 (-1.38%)

RCKT Rocket Pharmaceuticals
$44.80 /

+0.35 (+0.79%)

QURE uniQure
$32.25 /

-0.66 (-2.01%)

PASG Passage Bio
$16.92 /

-0.82 (-4.62%)

OXBDF Oxford Biomedica
$15.42 /

+0.21 (+1.38%)

ORTX Orchard Therapeutics
$6.17 /

+0.18 (+3.01%)

MGTX MeiraGTx
$13.59 /

-0.51 (-3.62%)

MBIO Mustang Bio
$3.16 /

-0.03 (-0.94%)

LZAGY Lonza
$61.10 /

+0.03 (+0.05%)

FRLN Freeline
$12.53 /

-0.11 (-0.87%)

FIXX Homology Medicines
$6.78 /

+0.04 (+0.59%)

CTLT Catalent
$114.83 /

+1.52 (+1.34%)

AVRO Avrobio
$11.37 /

+0.03 (+0.26%)

OXBDF Oxford Biomedica
$15.42 /

+0.21 (+1.38%)

10/09/20 RBC Capital
Oxford Biomedica still a strong investment proposition, says RBC Capital
07/27/20 RBC Capital
Oxford Biomedica initiated with an Outperform at RBC Capital
07/27/20 RBC Capital
Oxford Biomedica initiated with an Outperform at RBC Capital
AVRO Avrobio
$11.37 /

+0.03 (+0.26%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
02/17/21 Mizuho
Avrobio selloff on Bluebird news a buying opportunity, says Mizuho
CTLT Catalent
$114.83 /

+1.52 (+1.34%)

04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/02/21 Argus
Catalent price target raised to $140 from $130 at Argus
02/03/21 UBS
Catalent price target raised to $135 from $115 at UBS
02/03/21 RBC Capital
Catalent price target raised to $137 from $125 at RBC Capital
FIXX Homology Medicines
$6.78 /

+0.04 (+0.59%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
FRLN Freeline
$12.53 /

-0.11 (-0.87%)

03/22/21 Mizuho
Freeline initiated with a Buy at Mizuho
03/01/21 Stifel
Freeline initiated with a Buy at Stifel
11/25/20 Redburn
Freeline initiated with a Neutral at Redburn
09/01/20 Evercore ISI
Freeline initiated with an Outperform at Evercore ISI
LZAGY Lonza
$61.10 /

+0.03 (+0.05%)

02/23/21 JPMorgan
Lonza upgraded to Overweight from Neutral at JPMorgan
02/16/21 Deutsche Bank
Lonza price target raised to CHF 680 from CHF 630 at Deutsche Bank
02/10/21 Berenberg
Lonza price target raised to CHF 690 from CHF 410 at Berenberg
02/02/21 Morgan Stanley
Lonza price target raised to CHF 645 from CHF 630 at Morgan Stanley
MBIO Mustang Bio
$3.16 /

-0.03 (-0.94%)

12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
10/27/20 B. Riley
Mustang Bio selloff not related to fundamentals, says B. Riley Securities
10/26/20 Oppenheimer
Oppenheimer sees case study supporting MB-105 development in prostate cancer
10/26/20 H.C. Wainwright
Mustang Bio's Phase 1 data in PSCA-mCRPC 'encouraging,' says H.C. Wainwright
MGTX MeiraGTx
$13.59 /

-0.51 (-3.62%)

02/16/21 Chardan
MeiraGTx called a Top Pick for 2021 at Chardan
12/17/20 Chardan
Chardan boosts MeiraGTx target to $55, say buy shares 'now'
12/17/20 Piper Sandler
Piper says MeiraGTx not getting credit for RIX gene therapy that 'clearly works'
10/22/20 RBC Capital
MeiraGTx initiated with an Outperform at RBC Capital
ORTX Orchard Therapeutics
$6.17 /

+0.18 (+3.01%)

03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
PASG Passage Bio
$16.92 /

-0.82 (-4.62%)

04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/08/21 Chardan
Passage Bio price target raised to $45 from $35 at Chardan
03/04/21 Citi
Citi remains buyer of Passage Bio into first clinical data
03/04/21 Goldman Sachs
Passage Bio upgraded to Buy from Neutral at Goldman Sachs
QURE uniQure
$32.25 /

-0.66 (-2.01%)

04/26/21 Credit Suisse
uniQure assumed with an Outperform at Credit Suisse
04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Mizuho
uniQure upgraded to Buy on favorable risk/reward at Mizuho
04/01/21 Mizuho
uniQure upgraded to Buy from Neutral at Mizuho
RCKT Rocket Pharmaceuticals
$44.80 /

+0.35 (+0.79%)

04/01/21 SVB Leerink
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink
03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
RGNX Regenxbio
$34.25 /

-0.48 (-1.38%)

02/09/21 Morgan Stanley
Sarepta denied motion to dismiss 'Wilson Wolf' case, says Morgan Stanley
01/20/21 RBC Capital
Regenxbio price target raised to $50 from $42 at RBC Capital
01/06/21 Chardan
Regenxbio named top 2021 pick with $100 target at Chardan
SLDB Solid Biosciences
$5.09 /

+0.195 (+3.98%)

03/16/21 Chardan
Solid Biosciences price target raised to $20 from $12.50 at Chardan
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform at SVB Leerink
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink
TSHA Taysha Gene Therapies
$22.77 /

-0.35 (-1.51%)

04/12/21 Chardan
Taysha Gene Therapies price target raised to $67.50 from $60 at Chardan
03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
TSHA Taysha Gene Therapies
$22.77 /

-0.35 (-1.51%)

SLDB Solid Biosciences
$5.09 /

+0.195 (+3.98%)

RGNX Regenxbio
$34.25 /

-0.48 (-1.38%)

RCKT Rocket Pharmaceuticals
$44.80 /

+0.35 (+0.79%)

QURE uniQure
$32.25 /

-0.66 (-2.01%)

PASG Passage Bio
$16.92 /

-0.82 (-4.62%)

ORTX Orchard Therapeutics
$6.17 /

+0.18 (+3.01%)

MGTX MeiraGTx
$13.59 /

-0.51 (-3.62%)

MBIO Mustang Bio
$3.16 /

-0.03 (-0.94%)

FIXX Homology Medicines
$6.78 /

+0.04 (+0.59%)

CTLT Catalent
$114.83 /

+1.52 (+1.34%)

AVRO Avrobio
$11.37 /

+0.03 (+0.26%)

  • 07
    Apr
  • 19
    Mar
  • 22
    Jan
  • 08
    Jan
  • 10
    Dec
  • 23
    Nov
  • 20
    Nov
  • 19
    Nov
  • 24
    Sep
  • 07
    Aug
  • 11
    Jun
  • 11
    Jun
CTLT Catalent
$114.83 /

+1.52 (+1.34%)

SLDB Solid Biosciences
$5.09 /

+0.195 (+3.98%)

RGNX Regenxbio
$34.25 /

-0.48 (-1.38%)

RCKT Rocket Pharmaceuticals
$44.80 /

+0.35 (+0.79%)

QURE uniQure
$32.25 /

-0.66 (-2.01%)

PASG Passage Bio
$16.92 /

-0.82 (-4.62%)

FIXX Homology Medicines
$6.78 /

+0.04 (+0.59%)

CTLT Catalent
$114.83 /

+1.52 (+1.34%)

AVRO Avrobio
$11.37 /

+0.03 (+0.26%)

PASG Passage Bio
$16.92 /

-0.82 (-4.62%)

Hot Stocks
Rocket reports data from RP-L201 trial to treat LAD-I » 07:14
04/14/21
04/14
07:14
04/14/21
07:14
RCKT

Rocket Pharmaceuticals

$42.00 /

+1 (+2.44%)

Rocket Pharmaceuticals …

Rocket Pharmaceuticals announces positive interim data from the Company's Phase 1/2 clinical trial studying RP-L201, its lentiviral-based gene therapy for the treatment of severe Leukocyte Adhesion Deficiency-I (LAD-I). Severe LAD-I is a rare pediatric disease that prevents patients from adequately combating infections. LAD-I leads to recurrent life-threatening bacterial and fungal infections that respond poorly to antibiotics, require frequent hospitalizations and are ultimately fatal. These results were presented in a virtual poster session at the Clinical Immunology Society 2021 Annual Meeting. "Today's positive updates on our LAD-I program add to the growing body of encouraging evidence that RP-L201 may provide durable clinical benefit for patients with severe LAD-I who face recurrent, life-threatening infections from birth," said Jonathan Schwartz, M.D., Chief Medical Officer and Senior Vice President of Rocket. "We are very pleased to report that a second patient is nearing survival at one-year post-treatment, the primary outcome measure for the Phase 2 portion of the study. In all patients treated, CD18 expression has substantially exceeded the 4-10% threshold associated with survival into adulthood, with consistent peripheral blood vector copy number levels. Improved disease-related skin lesions, absence of new infections post-treatment, and no further requirements for prophylactic anti-infectives were also observed in both Phase 1 patients with prolonged follow-up. Initial evidence of engraftment and phenotypic correction was observed in two additional patients with shorter follow-up. These updates move us one step closer towards BLA/MAA filings in the US and Europe and eventual commercialization of a potentially curative option for the children facing this truly devastating disease. We look forward to providing more comprehensive Phase 2 results in the second half of 2021."

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$42.00 /

+1 (+2.44%)

RCKT Rocket Pharmaceuticals
$42.00 /

+1 (+2.44%)

04/01/21 SVB Leerink
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink
03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
RCKT Rocket Pharmaceuticals
$42.00 /

+1 (+2.44%)

  • 10
    Dec
RCKT Rocket Pharmaceuticals
$42.00 /

+1 (+2.44%)

Recommendations
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink » 07:49
04/01/21
04/01
07:49
04/01/21
07:49
RCKT

Rocket Pharmaceuticals

$44.45 /

+1.09 (+2.51%)

SVB Leerink analyst Mani…

SVB Leerink analyst Mani Foroohar raised the firm's price target on Rocket Pharmaceuticals to $66 from $61 and keeps an Outperform rating on the shares as he incorporates RP-L301 into his model. The analyst notes that Rocket is developing RP-L301, a lentiviral gene therapy, to treat Pyruvate Kinase Disease, a rare hematological disorder primarily affecting red blood cells.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$44.45 /

+1.09 (+2.51%)

RCKT Rocket Pharmaceuticals
$44.45 /

+1.09 (+2.51%)

03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
02/25/21 Piper Sandler
Rocket Pharmaceuticals momentum can continue through 2021, says Piper Sandler
RCKT Rocket Pharmaceuticals
$44.45 /

+1.09 (+2.51%)

  • 10
    Dec
RCKT Rocket Pharmaceuticals
$44.45 /

+1.09 (+2.51%)

Hot Stocks
Rocket Pharmaceuticals gets EMA PRIME designation for RP-L201 » 07:04
03/29/21
03/29
07:04
03/29/21
07:04
RCKT

Rocket Pharmaceuticals

$46.48 /

-1.08 (-2.27%)

Rocket Pharmaceuticals…

Rocket Pharmaceuticals announces that the European Medicines Agency,EMA, has granted Priority Medicines,PRIME, designation to RP-L201, the Company's investigational gene therapy for Leukocyte Adhesion Deficiency-I LAD-I. PRIME designation was granted based on encouraging preliminary safety and efficacy data from the ongoing Phase 1/2 clinical trial of RP-L201. "We are delighted that the EMA has awarded PRIME designation to RP-L201 for the treatment of LAD-I. PRIME completes the full complement of U.S. and EU accelerated regulatory designations for RP-L201 and signals that regulators recognize the high unmet medical need in treating this devastating pediatric disease and our gene therapy's potential to address the root cause of this disorder," said Kinnari Patel, Pharm.D., MBA, President and Chief Operating Officer of Rocket. "More than half of LAD-I patients suffer with a severe variant in which mortality occurs in up to 75% of children prior to age two in the absence of a successful bone marrow transplant. Securing all possible accelerated designations will enable us to collaborate with both the FDA and EMA to speed the delivery of a potentially curative option for these patients. We look forward to sharing initial Phase 2 data from our potentially registration-enabling LAD-I trial in the second quarter of 2021." The PRIME program aims to optimize development plans and speed up evaluation of medicines that may offer a major therapeutic advantage over existing treatments or benefit patients without treatment options. These medicines are considered priority medicines by the EMA and are intended to reach patients earlier. To be accepted for PRIME, a medicine has to show its potential to benefit patients with unmet medical needs based on early clinical data.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$46.48 /

-1.08 (-2.27%)

RCKT Rocket Pharmaceuticals
$46.48 /

-1.08 (-2.27%)

03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
02/25/21 Piper Sandler
Rocket Pharmaceuticals momentum can continue through 2021, says Piper Sandler
RCKT Rocket Pharmaceuticals
$46.48 /

-1.08 (-2.27%)

  • 10
    Dec
RCKT Rocket Pharmaceuticals
$46.48 /

-1.08 (-2.27%)

Recommendations
Rocket data shows durable impact for PKD, says William Blair » 11:08
03/22/21
03/22
11:08
03/22/21
11:08
RCKT

Rocket Pharmaceuticals

$57.00 /

+2.53 (+4.64%)

William Blair analyst…

William Blair analyst Raju Prasad keeps an Outperform rating on Rocket Pharmaceuticals after the company announced updated preliminary data from its Phase I trial of RP-L301 for pyruvate kinase deficiency. Rocket reported clinical updates from two PKD patients treated with RP-L301 and the data demonstrated a durable impact on hemoglobin levels, Prasad tells investors in a research note. Overall, RP-L301 continues to appear to be well tolerated and no safety or infusion-related issues were observed in either of the two patients up to six months post-treatment, at the time of the data cutoff, says the analyst. Prasad sees PKD as the most important indication for the lentiviral program.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$57.00 /

+2.53 (+4.64%)

RCKT Rocket Pharmaceuticals
$57.00 /

+2.53 (+4.64%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
02/25/21 Piper Sandler
Rocket Pharmaceuticals momentum can continue through 2021, says Piper Sandler
02/18/21
Fly Intel: Top five analyst initiations
RCKT Rocket Pharmaceuticals
$57.00 /

+2.53 (+4.64%)

  • 10
    Dec
RCKT Rocket Pharmaceuticals
$57.00 /

+2.53 (+4.64%)

Hot Stocks
Rocket announces update preliminary clinical data from Phase 1 trial » 07:07
03/22/21
03/22
07:07
03/22/21
07:07
RCKT

Rocket Pharmaceuticals

$54.47 /

-0.25 (-0.46%)

Rocket Pharmaceuticals…

Rocket Pharmaceuticals announces updated preliminary clinical data from its Phase 1 trial of RP-L301 for the treatment of Pyruvate Kinase Deficiency, showing durable normalization of hemoglobin levels up to 6 months following therapy and similar 3-month trends in the second patient treated. Additionally, results showed sustained safety and tolerability of RP-L301 6 months after treatment. "The positive updates on our PKD trial represent continued validation of RP-L301's robust potential benefit in addressing the challenges of PKD. We are pleased to report that updated patient 1 results show that RP-L301 continues to safely normalize hemoglobin levels as demonstrated by an increase from an average of approximately 7.4 g/dL at baseline to 13.9 g/dL at 6-months post-treatment with no transfusion requirements after hematopoietic reconstitution," said Jonathan Schwartz, M.D. Chief Medical Officer and Senior Vice President of Rocket. "A similar trend in hemoglobin and bilirubin normalization were observed at three months post-treatment in patient 2. We are excited to share this data as results show the potential of RP-L301 to address the extensive burden PKD places on patients and their families. We look forward to presenting more comprehensive and updated data at a scientific venue this year." RP-L301 continued to be well tolerated, with no serious safety issues or infusion-related complications observed up to 6-months post treatment.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$54.47 /

-0.25 (-0.46%)

RCKT Rocket Pharmaceuticals
$54.47 /

-0.25 (-0.46%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
02/25/21 Piper Sandler
Rocket Pharmaceuticals momentum can continue through 2021, says Piper Sandler
02/18/21
Fly Intel: Top five analyst initiations
RCKT Rocket Pharmaceuticals
$54.47 /

-0.25 (-0.46%)

  • 10
    Dec
RCKT Rocket Pharmaceuticals
$54.47 /

-0.25 (-0.46%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.